Novo Nordisk A/S (NVO) 은(는) 상장 기업입니다 헬스케어 섹터의 제약 산업에서 운영. 본사 소재지는 Bagsvaerd, Denmark. 현재 CEO는 Maziar Mike Doustdar.
NVO 을(를) 보유 IPO 날짜 1981-04-30, 77,406 명의 정규직 직원, 에 상장 New York Stock Exchange, 시가총액 $174.74B.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 that researches, develops, manufactures, and distributes medications globally across Europe, the Middle East, Africa, China, and North America. The company operates through two primary segments: Diabetes and Obesity Care, which offers treatments for diabetes, obesity, and cardiovascular conditions, and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Beyond pharmaceutical products, Novo Nordisk provides delivery devices such as insulin pens and growth hormone pens, as well as digital health solutions including smart insulin pens and dose guidance applications. The company has established strategic collaborations with UNICEF on childhood obesity initiatives and with Valo Health to develop cardiometabolic therapies.
